NEOS - ネオス・ファ―マシュ―ティカルズ (Neos Therapeutics Inc.) ネオス・ファ―マシュ―ティカルズ

 NEOSのチャート


 NEOSの企業情報

symbol NEOS
会社名 Neos Therapeutics Inc (ネオス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ネオス・セラピューティクス(Neos Therapeutics Inc.)は製薬会社である。同社は修正薬物送達技術プラットフォームを利用して製品の開発、製造及び商品化に従事する。同社は医薬品の開発、製造、販売に従事する。同社は注意欠如・多動性障害(ADHD)の治療向け製品を開発するプラットフォームを利用する。製品候補は、患者にやさしい徐放性(XR)口腔内崩壊錠剤(ODT)または液体懸濁剤剤形の薬剤である。ブランド製品と製品候補はADHD、メチルフェニデートとアンフェタミンの治療のための2つ以上の処方医薬品を含む。修正放出薬物送達プラットフォームは徐放性ODTと液体懸濁液投与形態の薬物を作製することを可能にする。同社はAdzenys XR-ODT、Cotempla XR-ODT、NT-0201の開発に従事する。   ネオス・ファ―マシュ―ティカルズは米国の医薬品会社。主に薬剤送達技術を利用し、既に商品化されている製薬の改良、開発に従事する。薬剤候補に、注意欠陥多動障害(ADHD)治療薬で、患者の負担が軽い徐放性タイプの経口薬を開発する。また、ADHD治療薬のメチルフェニデ―トとアンフェタミンの両方を取り入れた製薬も開発する。本社はキサス州。   Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
本社所在地 2940 N. Hwy. 360 Grand Prairie TX 75050 USA
代表者氏名 Alan Heller アラン・ヘラー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 972-408-1360
設立年月日 34639
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 138人
url www.neostx.com
nasdaq_url https://www.nasdaq.com/symbol/neos
adr_tso
EBITDA EBITDA(百万ドル) -48.18100
終値(lastsale) 4.18
時価総額(marketcap) 124036943.8
時価総額 時価総額(百万ドル) 118.99240
売上高 売上高(百万ドル) 36.57400
企業価値(EV) 企業価値(EV)(百万ドル) 150.86740
当期純利益 当期純利益(百万ドル) -60.12500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neos Therapeutics Inc revenues increased from $10.8M to $22.1M. Net loss decreased 17% to $29.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development - Balancing v decrease of 26% to $3.9M (expense) Other Income net increase from $175K to $594K (income).

 NEOSのテクニカル分析


 NEOSのニュース

   Neos Therapeutics (NEOS) Investor Presentation - Slideshow (NASDAQ:NEOS)  2020/06/24 18:55:04 Seeking Alpha
The following slide deck was published by Neos Therapeutics, Inc. in conjunction with this event.
   Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference  2020/06/16 12:00:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020  2020/05/04 20:05:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   Neos Therapeutics (NASDAQ: NEOS): Q4 2019 Earnings Snapshot  2020/03/13 12:09:08 news.alphastreet.com
— Neos Therapeutics Inc. (NASDAQ: NEOS) reported a fourth-quarter 2019 loss of $0.07 per share versus a loss of $0.03 per share expected. — Total…
   Neos Therapeutics: ADHD Franchise Needs To Return To Prescription Growth  2019/09/30 18:09:56 Seeking Alpha
Neos has executed the first part of the turnaround well. Net revenue per pack has made up for the smaller sales force and sequential declines in total prescript
   Neos Therapeutics (NEOS) Investor Presentation - Slideshow (NASDAQ:NEOS)  2020/06/24 18:55:04 Seeking Alpha
The following slide deck was published by Neos Therapeutics, Inc. in conjunction with this event.
   Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference  2020/06/16 12:00:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020  2020/05/04 20:05:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   Neos Therapeutics (NASDAQ: NEOS): Q4 2019 Earnings Snapshot  2020/03/13 12:09:08 news.alphastreet.com
— Neos Therapeutics Inc. (NASDAQ: NEOS) reported a fourth-quarter 2019 loss of $0.07 per share versus a loss of $0.03 per share expected. — Total…
   Neos Therapeutics: ADHD Franchise Needs To Return To Prescription Growth  2019/09/30 18:09:56 Seeking Alpha
Neos has executed the first part of the turnaround well. Net revenue per pack has made up for the smaller sales force and sequential declines in total prescript
   Neos Therapeutics: ADHD Franchise Needs To Return To Prescription Growth  2019/09/30 18:09:56 Seeking Alpha
Neos has executed the first part of the turnaround well. Net revenue per pack has made up for the smaller sales force and sequential declines in total prescript
   Neos Therapeutics (NEOS) Reports Q2 Loss, Misses Revenue Estimates  2019/08/08 12:35:07 Zacks Investment Research
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Neos Therapeutics Enters Oversold Territory  2019/05/24 10:56:00 Zacks Investment Research
Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q1 2019 Results - Earnings Call Transcript  2019/05/09 18:06:16 Seeking Alpha
Neos Therapeutics, Inc. (NASDAQ:NEOS) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Jerry McLaughlin - Chief Executive Officer Ri
   Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates  2019/05/09 12:35:09 Zacks Investment Research
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (医薬品 米国株 ネオス・ファ―マシュ―ティカルズ NEOS Neos Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)